Longboard Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$2.33B
-2.24
50
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
emptyResult
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 50 full-time employees. The company went IPO on 2021-03-12. The firm is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). The company is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The firm plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The company is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The firm is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Recently from Cashu
Longboard Pharmaceuticals Expands Neurological Treatment Pipeline with Strategic Acquisition of Lundbeck
Longboard Pharmaceuticals Advances Treatment for Neurological Disorders with Strategic Acquisition Longboard Pharmaceuticals, Inc. is making significant strides in the field of neurological disease tr…
Longboard Pharmaceuticals Enhances Neurological Treatments with Acquisition and Promising Clinical Advancements
Longboard Pharmaceuticals Advances Neurological Treatment with Strategic Acquisition and Promising Clinical Trials Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, recently…